# Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

> **NCT01382238** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 20 (actual)

## Conditions studied

- Infections, Human Immunodeficiency Virus and Herpesviridae

## Interventions

- **DRUG:** Dolutegravir 50 mg tablet
- **DRUG:** Dolutegravir 50 mg oral granules

## Key facts

- **NCT ID:** NCT01382238
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382238, "Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01382238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*